LRP1 inhibition leads to an enhanced sensitivity to lipopolysaccharide (LPS), a stimulus of Gram-negative bacterial infections, activating the production of pro-inflammatory cytokines through NK-kB and JNK pathways (64, 65). The gene discussed is MAPK8; the disease is gram-negative bacterial infections.